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Abstract Thrombotic thrombocytopenic purpura (TTP)
is an autoimmune disorder characterised by fever, micro-
angiopathic haemolytic anaemia, renal insufficiency, and
thrombocytopenia. Neurological involvement, a prominent
component of TTP, is characterised by a variety of brain
lesions which include reversible cerebral oedema or mag-
netic resonance imaging (MRI) features of reversible
posterior leukoencephalopathy syndrome (RPLS). TTP is
frequently associated with deficiency of the von Wille-
brand factor-cleaving protease, ADAMTS13.
Here, we report a case of TTP with severe acute
encephalopathy. Posterior leukoencephalopathy and brain-
stem oedema with triventricular hydrocephalus were
observed on MRI. The low activity of ADAMTS13 was not
observed and ADAMTS-13 antibodies were absent. Neu-
rological symptoms and patient’s condition were com-
pletely resolved by plasma exchange therapy in addition to
high dose of methylprednisolone.
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Introduction
Posterior reversible leukoencephalopathy syndrome (RPLS)
is a recently proposed clinico-neuroradiological entity
presenting with a variety of neurological features [1].
These, although potentially devastating, are reversible on
prompt diagnosis and appropriate treatment. Delayed
diagnosis can lead to long-term neurological disability [2].
A relatively symmetrical pattern of involvement, typically
in the subcortical white matter and occasionally in the
cortex of the posterior circulation area of the brain is evi-
dent on magnetic resonance imaging (MRI) studies [1].
Common causes of RPLS are hypertensive encephalopa-
thy, eclampsia, cyclosporin-A neurotoxicity, and uremic
encephalopathy. Although the majority cases of RPLS are
associated with hypertensive disorders, it has also been
described in normotensive patients in association with
thrombotic thrombocytopenic purpura (TTP) [3].
Case report
A previously healthy 53-year-old Caucasian man was
admitted in an emergency department for the rapid onset of
disturbances of gait, dizziness, urinary incontinence and
lethargy. The pulse rate was 80 beats/min, temperature
38C and blood pressure was 260/180 mmHg, partially
decreased by administered nitroprusside, furosemide and
clonidine.
White and red blood cells count and haemoglobin were
normal (7.5 9 103/ll, 5.55 9 106/ll, 15.7 g/dl). Platelet
count (86.0 9 103/ll), LDH (642 mg/dl), serum creatinine
(1.90 mg/dl), and urea (53 mg/dl) were out of normal
range. A brain CT scan showed an enlargement of the
lateral and third ventricles. The day after, the patient
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started complaining weakness in lower limbs, mental
confusion and impaired attention and because of worsening
of symptoms he was admitted to our department. He was
lethargic and neurological examination showed hyperre-
flexia and pathological reflexes in all four limbs. An
electroencephalogram (EEG) was characterised by marked
slowness in the left posterior hemisphere without evidence
of epileptic activity.
MRI of the brain revealed abnormal signal bilaterally in
the white matter of cerebral and cerebellar hemispheres
with the involvement of midbrain and cerebellar peduncles
(Fig. 1a). A triventricular hydrocephalus, presumably
caused by brainstem oedema, was observed.
A lumbar puncture revealed a limpid and uncoloured
cerebrospinal fluid (CSF) with normal cell count (0.8/
mm3) and a barely elevated total protein concentration
(77 mmg/dl, normal value\40 mg/dl) with positive Pandy
reaction. Polymerase chain reaction assay of Epstein–Barr
virus (EBV)-DNA, Herpes simplex virus (HSV)-DNA,
Cytomegalovirus (CMV)-DNA was negative. CSF cultures
had no bacterial, viral and fungal growth.
After 2 days from admission, laboratory findings
revealed a platelet count of 58.0 9 103/ll. Lactate dehy-
drogenase (LDH): 562 mg/dl (normal 200–480 mg/dl);
serum creatinine: 3.04 mg/dl (normal 0.67–1.17 mg/dl);
urea: 106 mg/dl (normal 10–50 mg/dl); bilirubin level:
1.42 mg/dl (normal 0.3–1.1 mg/dl); AST: 38 U/l (max.
37 U/l); GGT: 72 U/l (normal 8–61 U/l); rheumatoid fac-
tor: 106 IU/ml; coagulation profile, complement C3 and
C4: normal.
The results of serological tests for acute infection with
cytomegalovirus, Epstein–Barr virus, Herpes simplex
virus, and Herpes zoster virus were negative. Serological
tests of antibodies to hepatitis B and C virus and human
immunodeficiency virus were also negative.
Tests for serum antibodies, including anticardiolipin,
perinuclear anti-neutrophil cytoplasmatic antibodies (pAN-
CA), cytoplasmic anti-neutrophil cytoplasmatic antibodies
Fig. 1 T2-weighted axial and
T1-weighted sagittal section
MRI. a Two days after the
admission to our department:
hyperintensity in the bilateral
white matter of cerebral and
cerebellar hemispheres with
involvement of midbrain and
cerebellar peduncles, b after
2 weeks, c 3 months later:
almost complete resolution of
abnormal signal on MRI
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(cANCA), antinuclear antibody (ANA), anti-double stran-
ded DNA antibody (dsDNA), anti-smooth muscle antibodies
(anti-SM), anti-smooth muscle-ribonucleoprotein (anti-SM
RNP), anti-Sjo¨gren’s syndrome A (anti-SSA) and anti-
Sjo¨gren’s syndrome B (anti-SSB) were negative.
A 5-day regimen of high-dose intravenous administra-
tion of methylprednisolone (1 g/day) was started and
within a week, an improvement of confusion and atten-
tional difficulties was observed.
A diagnosis of RPLS in a patient with TTP was sug-
gested by a second platelet count of 40.0 9 103/ll, the
presence of schistocytes in the peripheral blood smear, in
addition to acute renal failure, confusion and other neuro-
logical symptoms, and MRI features. A blood sample of
the patient was sent to a reference laboratory for ADAM-
TS-13 assays. The patient was transferred to the haema-
tology division. More details regarding clinical and
therapeutic aspects of this recovery are reported elsewhere
[4]. Briefly, a prompt plasma exchange therapy was started,
with daily exchanges of one plasma volume while steroid
therapy was continued. After eight daily plasma exchange
without complete remission, an additional immunosup-
pressive treatment with rituximab (at a standard dosage of
375 mg/m2) was administered weekly for 4 weeks. This
treatment was continued despite ADAMTS-13 activity was
100% and no antibodies against ADAMTS-13 were
detected. The platelet count was normalised and the neu-
rological status improved progressively. The patient
became totally normal after 3 months and a brain MRI
showed nearly complete resolution of brainstem oedema
and the T2 signal changes (Fig. 1c). Six months later, his
neurological examination was normal. Twenty-four months
later, no relapses have been observed and the patient is still
healthy.
Discussion and conclusion
RPLS, also known as posterior reversible encephalopathy
syndrome (PRES), is a clinical condition characterised by
an acute or subacute onset of neurological symptoms
(headache, altered mental status, confusion, and drowsi-
ness), visual disturbance (hemianopsia, visual neglect, and
cortical blindness), seizures associated with imaging find-
ings of reversible cortical and subcortical vasogenic brain
edema [5]. Eclampsia, hypertensive emergency, renal
failure, autoimmune diseases and immunosuppressive
therapy are common precipitating factors in RPLS [6].
The endothelial injury and the following release of
factors promoting platelet activation and hyaline micro-
thrombi formation in addition to blood–brain barrier injury
are the most important pathophysiologic mechanisms for
TTP-associated RPLS [3]. These factors could cause
hypoperfusion leading to stroke or, on the contrary, cere-
bral micro-haemorrhages due to thrombocytopenia and
hypertension [7].
We present a patient with TTP, elevated blood pressure
and posterior vasogenic oedema on MRI consistent with
posterior leukoencephalopathy. The course of these MRI-
featured lesions permitted us to define it as reversible.
Plasma exchange represents the first treatment of TTP
patients with or without ADAMTS-13 deficiency. These
two groups differ in the frequency of relapses. In fact,
patients without ADAMTS-13 deficiency almost never
relapse, on the contrary, about 50% of the patients with
ADAMTS-13 deficiency suffer relapse within 2 years [8].
In our patient, in addition to the methylprednisolone,
plasma exchange was started when the diagnosis of TTP
was done, and as previously reported by other authors
[9, 10], a rapid improvement of haemolysis and a nor-
malization of platelet count were seen.
This case shows the importance of the recognition and
prompt treatment of patient with TTP and further
strengthens the evidence that, even if the demonstration of
plasma level of ADAMTS-13 and its antibodies are diag-
nostic, the absence of this diagnostic test justify the
beginning of therapy without waiting the test results.
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